Latest Posts

30

May 24

Partex and Singapore’s Experimental Drug Development Centre collaborate to bring forward an innovative approach for early drug discovery and development

Frankfurt, Germany, 3rd June 2024, 9am CET Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled...
Read More

22

Apr 24

Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven Asset Search and Evaluation

Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to...
Read More

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More
Try Ontosight® For Free

Author name: Gunjan Bhardwaj

Gunjan Bhardwaj is the founder and CEO of Innoplexus, a leader in AI and analytics as a service for life science industries. With a background at Boston Consulting Group and Ernst & Young, he bridges the worlds of AI, consulting, and life science to drive innovation.

Partnering to unlock the true potential of cannabis in medical care

AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering to unlock the potential of phytocannabinoids in designing medical therapies. ESCHBORN, Germany, Oct 25th, 2021 – Innoplexus, a global leader in AI-based drug discovery and development; and DrD, an innovative biotechnology company focused on phytocannabinoids, are partnering to accelerate the clinical development and market authorization of …

Partnering to unlock the true potential of cannabis in medical care Read More »

Machine learning as an indispensable tool for Biopharma

The cost of developing a new drug roughly doubles every nine years (inflation-adjusted) aka Eroom’s law. As the volume of data for drug discovery and development explodes, the ability of Pharma and medical practitioners to keep up and accelerate drug discovery becomes more challenging. In contrast, the software industry reaps the benefits of Moore’s law …

Machine learning as an indispensable tool for Biopharma Read More »

FDA supports AI for drug development

AI technologies are more widely used in the pharmaceutical industry today to enable for its extensive review of scientific and medical literature. Extensive data obtained through AI can support the discovery of potential biomarkers, accelerate drug development and identify repurposing opportunities.1 The FDA sees tremendous potential in technologies such as machine and deep learning in healthcare. …

FDA supports AI for drug development Read More »

How Artificial Intelligence is accelerating research to treat COVID-19

The World Health Organization announced a pandemic in April 2020. Artificial intelligence technologies have presented effective methods for accelerating research, monitoring spread of infection and to identify effective treatments to fight with the novel coronavirus. Here are the various ways in which artificial intelligence has proved to be effective during this pandemic. I. Monitoring the …

How Artificial Intelligence is accelerating research to treat COVID-19 Read More »

AI as an effective tool to combat the novel coronavirus pandemic

First discovered in December 2019 in China, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had spread worldwide. By April 2020 it was declared a pandemic by the World Health Organization (WHO). There is now a race to developing a vaccine to cure COVID-19 (coronavirus disease 2019). COVID-19, which has affected more than 7 Million …

AI as an effective tool to combat the novel coronavirus pandemic Read More »

Real-time, real-world data in modern clinical research

The pharmaceutical industry is facing a pivotal time in the evolution of clinical research and trials. Emerging technologies with unprecedented potential are improving trial efficiency, safety, and accuracy. Improved methods of data collection and handling are at the forefront of these developments, leading to better procedures and enhanced outcomes. Real-time data makes a huge difference. …

Real-time, real-world data in modern clinical research Read More »